{"protocolSection": {"identificationModule": {"nctId": "NCT00181155", "orgStudyIdInfo": {"id": "IRB: 04-10-12-06"}, "secondaryIdInfos": [{"id": "5R01HL061912-14", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5R01HL061912-14"}], "organization": {"fullName": "Johns Hopkins University", "class": "OTHER"}, "briefTitle": "Intravenous Allopurinol in Heart Failure", "officialTitle": "Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-11"}, "primaryCompletionDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-12", "studyFirstSubmitQcDate": "2005-09-12", "studyFirstPostDateStruct": {"date": "2005-09-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-11", "resultsFirstSubmitQcDate": "2016-01-06", "resultsFirstPostDateStruct": {"date": "2016-02-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-28", "lastUpdatePostDateStruct": {"date": "2017-05-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Robert G. Weiss", "investigatorTitle": "Professor of Medicine and Radiology", "investigatorAffiliation": "Johns Hopkins University"}, "leadSponsor": {"name": "Johns Hopkins University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.", "detailedDescription": "Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts. The investigators developed a means to directly measure creatine kinase flux, the major energy reserve of the heart, in the human heart exploiting new magnetic resonance technologies.\n\nThe investigators propose to study 10 healthy subjects and up to 25 with heart failure (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol."}, "conditionsModule": {"conditions": ["Congestive Heart Failure"], "keywords": ["metabolism", "congestive heart failure", "allopurinol", "Adenosine triphosphate (ATP)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Allopurinol", "type": "EXPERIMENTAL", "description": "One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.", "interventionNames": ["Drug: Allopurinol"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Allopurinol", "description": "intravenous infusion of allopurinol (300mg)", "armGroupLabels": ["Allopurinol"], "otherNames": ["Aloprim"]}, {"type": "DRUG", "name": "Placebo", "description": "intravenous infusion of 50 ml dose of 5% dextrose", "armGroupLabels": ["Placebo"], "otherNames": ["5% Dextrose"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion", "description": "Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion", "timeFrame": "Onset of imaging acquisition."}, {"measure": "Myocardial CK Flux Post Intravenous Allopurinol Infusion.", "description": "The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.", "timeFrame": "acute (within 15 minutes of single infusion)"}], "secondaryOutcomes": [{"measure": "Cardiac PCr/ATP Pre Intravenous Infusion", "description": "The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.", "timeFrame": "Onset of image acquisition."}, {"measure": "Cardiac PCr/ATP Post Intravenous Infusion", "description": "The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.", "timeFrame": "acute (within 15 minutes of single infusion)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18 years\n* The patient is willing and able to provide informed consent\n* Clinical diagnosis of chronic heart failure\n* Ejection fraction (EF) \\< 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography\n* No significant coronary disease at cardiac catheterization\n* New York Heart Association (NYHA) Class I-IV symptoms\n* Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.\n\nExclusion Criteria:\n\n* Metallic implant prohibiting magnetic resonance (MR) evaluation\n* Inability to lie flat for MR study\n* Administration of additional investigational drugs\n* Calculated creatinine clearance \\< 50 mL/min\n* Allergy to allopurinol\n* Current gout flare\n* Currently taking oral allopurinol", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Robert G Weiss, MD", "affiliation": "Johns Hopkins University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Johns Hopkins Hospital", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}]}, "referencesModule": {"references": [{"pmid": "22361399", "type": "DERIVED", "citation": "Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012 Feb 28;59(9):802-8. doi: 10.1016/j.jacc.2011.10.895."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study drug allocation was randomized in a 4:1 fashion by the research pharmacy. Participants were randomized to Placebo only for the purposes of blinding; Adverse Events were collected for the Placebo arm.", "recruitmentDetails": "Participants with Non-Ischemic Cardiomyopathy were recruited as approved by the Johns Hopkins Institutional Review Board for Human Investigation.", "groups": [{"id": "FG000", "title": "Allopurinol", "description": "Each participant underwent magnetic resonance spectroscopy before and following infusion of either allopurinol 300mg or placebo."}, {"id": "FG001", "title": "Placebo", "description": "Each participant underwent magnetic resonance spectroscopy before and following infusion of either allopurinol 300mg or placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Intravenous Allopurinol", "description": "We randomized patients with nonischemic cardiomyopathy in a double-blind fashion to allopurinol (300 mg intravenously) or placebo infusion, 4-to-1, the latter for purposes of blinding only. The myocardial concentrations of ATP and creatine phosphate (PCr) and the rate of adenosine triphosphate (ATP) synthesis through CK (CK flux) were determined by 31-Phosphorus (31P) magnetic resonance spectroscopy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.8", "spread": "12.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion", "description": "Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion", "populationDescription": "Data were analyzed for all participants who completed the MRS per protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/g/sec", "timeFrame": "Onset of imaging acquisition.", "groups": [{"id": "OG000", "title": "Baseline", "description": "Each participant underwent baseline MRS imaging prior to infusion of Aloprim 300 mg in 50 cc of 5% Dextrose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.07", "spread": "1.27"}]}]}]}, {"type": "SECONDARY", "title": "Cardiac PCr/ATP Pre Intravenous Infusion", "description": "The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.", "populationDescription": "Data were analyzed for all participants who completed the MRS per protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Onset of image acquisition.", "groups": [{"id": "OG000", "title": "Baseline", "description": "Each participant underwent baseline MRS imaging prior to infusion of Aloprim 300 mg in 50 cc of 5% Dextrose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.58", "spread": "0.41"}]}]}]}, {"type": "PRIMARY", "title": "Myocardial CK Flux Post Intravenous Allopurinol Infusion.", "description": "The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.", "populationDescription": "Data were analyzed for all participants who completed the MRS per protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/g/sec", "timeFrame": "acute (within 15 minutes of single infusion)", "groups": [{"id": "OG000", "title": "Intravenous Allopurinol", "description": "Infused Aloprim 300 mg in 50cc 5% dextrose. Post MRS data acquired on each subject."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.87", "spread": "1.82"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.007", "pValueComment": "vs. baseline", "statisticalMethod": "Two-sided paired t tests", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Cardiac PCr/ATP Post Intravenous Infusion", "description": "The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.", "populationDescription": "Data were analyzed for all participants who completed the MRS per protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "acute (within 15 minutes of single infusion)", "groups": [{"id": "OG000", "title": "Intravenous Allopurinol", "description": "Infused Aloprim 300 mg in 50cc of 5% dextrose. Post infusion MRS data acquired on each subject."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.75", "spread": "0.59"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.02", "pValueComment": "vs. baseline", "statisticalMethod": "Two-sided paired t tests", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Arm 1 - Intravenous Allopurinol", "description": "Each participant received pre and post MRS images following infusion of 50 cc of Aloprim 300mg in 5% Dextrose.", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 0, "otherNumAtRisk": 13}, {"id": "EG001", "title": "Arm 2 - Placebo", "description": "Each participant received pre and post MRS images following infusion of 50 cc of 5% Dextrose (equivalent volume to active treatment arm).", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The limitations of the current study include the small placebo group sample size and the etiologic heterogeneity of the nonischemic cardiomyopathy group."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Robert G. Weiss, MD", "organization": "Johns Hopkins University", "email": "rweiss@jhmi.edu", "phone": "410-955-1703"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000493", "term": "Allopurinol"}], "ancestors": [{"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000006074", "term": "Gout Suppressants"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000016166", "term": "Free Radical Scavengers"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M3834", "name": "Allopurinol", "asFound": "African", "relevance": "HIGH"}, {"id": "M3595", "name": "Adenosine", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}